Antipsychotic Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Antipsychotic Drugs Market Analysis
The antipsychotic drugs market is expected to register a CAGR of 5.6% over the forecast period.
The emergence of the COVID-19 pandemic significantly impacted people with psychotic disorders due to lockdown restrictions, a high influx of COVID-19 patients, and an increased risk of contracting COVID-19. Hence, COVID-19 affects the ongoing treatment procedure, diagnosis, and treatment of new patients. For instance, according to a research article published in Nature in January 2021, dementia patients were at higher risk of contracting COVID-19 than non-dementia patients. Hence, COVID-19 had a significant impact on the market. Furthermore, the long-term effects of COVID-19 on people with psychotic disorders, along with higher adoption of telemedicine services in the post-pandemic, may have a further impact on the demand for antipsychotic drugs over the forecast period.
The rise in the prevalence of mental health disorders, such as schizophrenia and bipolar disorder, amongst the population, along with rising initiatives by the government and other private organizations for the awareness of psychotic disorders, is majorly driving the market. For instance, according to data published by the World Health Organisation (WHO) in March 2023, Approximately 55 million people in the globe have dementia, and 60% of them are from low and middle-income countries in 2022. Further, as per the same source, almost 10 million new cases of dementia are reported globally. In addition, increasing efforts by the World Health Organisation to address dementia and growing awareness of mental health are driving demand for antipsychotic drugs and fueling significant market growth during the forecast period.
Furthermore, as per the World Health Organization data published in February 2021, Depression is a common mental disorder affecting over 280 million people of all ages worldwide. Thus, the high prevalence of mental disorders is boosting the demand for antipsychotic drugs during the study period. Rising advancement in the research field for introducing blockbuster drug molecules also supports market growth. For instance, in January 2023, Eisai Co., Ltd. received the Food and Drug Administration approval for Leqembi via the Accelerated Approval Pathway for treating Alzheimer's disease. This introduction of advanced drug options for neurological disorders is further driving the adoption of antipsychotic drugs among the patient population globally.
Therefore, a growing number of mental disorder patients, awareness initiatives on mental disorders, and new product introductions are driving antipsychotic drug adoption and supporting market growth. While addiction caused due to antipsychotic drugs and the patent expiry of major drugs are the key factors hampering the development of the market.
Antipsychotic Drugs Market Trends
Schizophrenia is Expected to Hold Major Share in the Market over the Forecast Period
Schizophrenia is a severe mental disorder that affects a large number of people across the globe. Distortions in thinking, emotions, and sense of self and behavior mainly characterize the disease. The increasing prevalence of Schizophrenia and associated disorders is the key factor driving the market's growth over the forecast period. This, coupled with the rising geriatric population, who are more susceptible to late-onset Schizophrenia, is also raising the demand for available drugs for Schizophrenia.
For instance, according to the World Health Organization, in 2022, Schizophrenia affected 24 million people worldwide. Furthermore, due to the increasing incidence of Schizophrenia among the older population, this number is likely to increase owing to the global aging population. For instance, according to a report published by United Nations in 2022, the share percentage of older adults worldwide is projected to increase from 10% in 2022 to 16% by 2050. The aging population is more susceptible and prone to neurological disorders and continues to experience worse situations later in life. This results in increased demand for antipsychotic drugs among these patient groups for Schizophrenia. For instance, according to an article published by Informa UK Limited in April 2022, aging populations in developed nations are leading to more older adults with psychiatric disorders. Also, according to an article published by Healthline India in May 2022, people with Schizophrenia experienced the worst symptoms in the first episode of psychosis, which increases in later life as age increases. Thus, the increasing geriatric population, along with the increased susceptibility towards Schizophrenia, is driving the product demand and is instrumental for segmental growth.
Additionally, with the growing burden of Schizophrenia, the demand for advanced therapeutics is increasing. Hence, the launch of novel drugs in the market is further expected to boost the market growth over the forecast period. For instance, on September 2021, the Food and Drug Administration accepted Teva Pharmaceuticals and MedinCell's new drug application (NDA) for TV-46000/mdc-IRM, used to treat Schizophrenia.
Thus, the increased prevalence of Schizophrenia and the rising number of product approval by the regulatory authorities are likely to boost the segmental growth during the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to dominate the market share, owing to its well-established healthcare infrastructure and better regulatory framework. Furthermore, the increasing prevalence of mental disorders and government support in the countries of this region for mental disorders are also anticipated to fuel regional growth over the study period. For instance, according to a report published by National Center for Biotechnology Information in March 2023, 57.8 million adults in the United States had mental illness in 2021. According to an article published by National Center for Biotechnology Information in March 2021, approximately 6.2 million people in the United States of 65 years and older had Alzheimer's dementia in 2021. Also, per the report published by the Alzheimer Society of Canada, in September 2022, an estimated 1.7 million Canadians are expected to live with dementia by 2050. This increasing patient population over the year in this region is raising the demand for antipsychotic drugs. It is anticipated to foster the growth of this region in the market over the forecast period.
Furthermore, the companies are focusing on adopting various business strategies such as collaborations, product launches, acquisitions, and partnerships to withhold their position in the antipsychotic drug market is likely to boost the market growth. For instance, in October 2022, Lupin launched Paliperidone Extended-Release Tablets to treat schizophrenia in the United States.
Hence, the rising prevalence of mental illness, schizophrenia, and dementia in the region and increased R&D efforts by market players to introduce advanced drugs are expected to drive market growth in the forecast period.
Antipsychotic Drugs Industry Overview
The market for antipsychotic Drugs is moderately competitive and consists of global players as well as local players. Some of the key players in the antipsychotic drugs market are AbbVie Inc., Pfizer Inc., Otsuka Pharmaceutical Co, Ltd., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, and Eli Lily and Company.
Antipsychotic Drugs Market Leaders
-
Eli Lily and Company
-
Johnson and Johnson
-
Pfizer Inc.
-
AstraZeneca plc
-
Otsuka Pharmaceutical Co, Ltd.
*Disclaimer: Major Players sorted in no particular order
Antipsychotic Drugs Market News
- In January 2023, Luye Pharma Group received the Food and Drug Administration approval for Rykindo with the aim to treat Schizophrenia and bipolar 1 disorder.
- In February 2022, Alkermes plc released positive results from ENLIGHTEN-early, a phase 3b study that evaluate the study of LYBALVI in schizophrenia disease.
- In January 2022, Otsuka Pharmaceutical Co., Ltd., its subsidiary Otsuka American Pharmaceutical, Inc., and Lundbeck, Inc. received the Food and Drug Administration approval for the supplemental new drug application of REXULTI for Schizophrenia in 13 to 17-year-old patients.
Antipsychotic Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Mental Disorders
- 4.2.2 Increasing Focus of Governments and Health Care Organizations on Mental Health
- 4.2.3 Constant Investment in Research and Development
-
4.3 Market Restraints
- 4.3.1 Addiction Caused Due to the Antipsychotic Drugs
- 4.3.2 Patent Expiry of Major Drugs
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Application
- 5.1.1 Schizophrenia
- 5.1.2 Bipolar Disorder
- 5.1.3 Unipolar Disorder
- 5.1.4 Dementia
- 5.1.5 Others
-
5.2 By Drug Classification
- 5.2.1 First Generation (Typical)
- 5.2.2 Second Generation (Atypical)
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Eli Lily and Company
- 6.1.2 AstraZeneca plc
- 6.1.3 GlaxoSmithKline plc
- 6.1.4 Johnson & Johnson
- 6.1.5 Otsuka Pharmaceutical Co, Ltd.
- 6.1.6 Pfizer Inc.
- 6.1.7 AbbVie Inc.
- 6.1.8 H. Lundbeck A/S
- 6.1.9 Teva Pharmaceutical Industries Ltd.
- 6.1.10 Sumitomo Pharma Co., Ltd.
- 6.1.11 Alkermes
- 6.1.12 Intra-Cellular Therapies, Inc.
- 6.1.13 Acadia Pharmaceuticals Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAntipsychotic Drugs Industry Segmentation
As per the scope of the report, antipsychotic drugs, also called antipsychotic medications or simply antipsychotics, are prescribed as short or long-term treatment of mental health problems. These drugs help alleviate and control psychotic symptoms such as anxiety, depression, delusions, hallucinations, or mania. The Antipsychotic Drugs Market is Segmented by Application (Schizophrenia, Bipolar disorder, Unipolar depression, Dementia, Others), Drug Classification (First Generation and Second Generation), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Application | Schizophrenia | |
| Bipolar Disorder | ||
| Unipolar Disorder | ||
| Dementia | ||
| Others | ||
| By Drug Classification | First Generation (Typical) | |
| Second Generation (Atypical) | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Antipsychotic Drugs Market Research FAQs
What is the current Global Antipsychotic Drugs Market size?
The Global Antipsychotic Drugs Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)
Who are the key players in Global Antipsychotic Drugs Market?
Eli Lily and Company, Johnson and Johnson, Pfizer Inc., AstraZeneca plc and Otsuka Pharmaceutical Co, Ltd. are the major companies operating in the Global Antipsychotic Drugs Market.
Which is the fastest growing region in Global Antipsychotic Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Antipsychotic Drugs Market?
In 2024, the North America accounts for the largest market share in Global Antipsychotic Drugs Market.
What years does this Global Antipsychotic Drugs Market cover?
The report covers the Global Antipsychotic Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Antipsychotic Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Antipsychotic Drugs Industry Report
Statistics for the 2024 Antipsychotic Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Antipsychotic Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
